S2Medical AB (S2M.XSTO) Quality Score
Valuation is the primary weakness (avg 0/100). No single area scores well.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Negative earnings, no valuation support
Negative FCF, no valuation support
Above 10% CAGR, strong compounder
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Heavy dilution above 5%
Expanded 3+pp, strong improvement
Net cash position, no leverage concern
Below 8%, may not cover cost of capital
S2Medical AB (S2M.XSTO) quality: score, margins and returns
S2Medical AB (S2M.XSTO) scores 40/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 6 metrics each scored 0 to 100, on -18.5% operating margins and -14.7% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.
Frequently asked
Is S2Medical AB (S2M.XSTO) a high-quality business?+
S2Medical AB scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a -18.5% operating margin and a -14.7% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does S2Medical AB's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from S2M.XSTO's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where S2Medical AB scores well and where it falls behind.
What is S2Medical AB's return on invested capital (ROIC)?+
S2Medical AB earns about -14.7% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to S2M.XSTO's margins and growth on this scorecard to judge durability.
How profitable is S2Medical AB?+
S2Medical AB runs an operating margin of about -18.5% and a net margin of about -60.5%. Revenue has grown at roughly 16.9% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.
Related stocks: Medical Instruments & Supplies
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.